-
Decentralized Trials: Bringing Clinical Trials Closer to the Patient
While participating in clinical trials can provide substantial benefits to people with lung cancer, the resources required to do so may pose significant hurdles, especially to... -
LUNGevity's International Lung Cancer Survivorship Conference
LUNGevity's 2023 International Lung Cancer Survivorship Conference features something for everyone! Our lineup of internationally renowned lung cancer experts will be covering a... -
We have succeeded in targeting KRAS G12C mutations. Now what?
We currently have two FDA-approved drugs, sotorasib and adagrasib, that are used to treat advanced-stage NSCLC with KRAS G12C mutations. Watch the discussion with guest speakers... -
2023 ASCO: Highlights of Lung Cancer Research
Recently, members of LUNGevity Foundation joined thousands of attendees from the US and around the world, including oncologists, scientists, biotech and pharmaceutical... -
Linda I. Shares Her Story
I was told on October 11, 2007, that I had non-small cell lung cancer (NSCLC). I was 46 years old with 2 kids — 7 and 12 year olds — at home waiting for me. I had an MRI and PET... -
Navigating Hope: How Comprehensive Biomarker Testing is Guiding Lung Cancer Care
Join us for a discussion on lung cancer biomarkers to learn what biomarker testing is, why it’s important, and how it can be used to optimize your treatment plans. We are thrilled... -
Tracing the Clues of a Global Killer: How Dr. Charles Swanton’s Research Is Shedding New Light on Lung Cancer
As Chief Investigator of the groundbreaking Cancer Research UK (CRUK) TRACERx study, you could say that Dr. Charles Swanton is having a moment. Launched nine years ago, TRACERx... -
EGFR+ Lung Cancer: Going Beyond Osimertinib
Learn about what's next once osimertinib stops working in EGFR+ lung cancer. EGFR Resisters co-founders Jill Feldman and Ivy Elkins, and 2021 EGFR Resisters/LUNGevity Foundation... -
The Basics of Neuroendocrine Tumors (NETs)
Our lung tissue is made of different kinds of cells, including neuroendocrine cells. If these cells develop changes in their genome, they can begin to grow out of control and... -
Caregiver Spotlight: Myra Aldarondo
In the spring of 2021, Myra’s husband Kelvin had COVID-19. After, he had a lingering cough and shortness of breath. His chest hurt a bit when he breathed. They assumed it was... -
A Survivor’s Experience with Biomarker Testing and TKI Treatments
Back in 2013, when Dan Cadigan was first diagnosed with stage III lung cancer, his treatment options were limited to surgery followed by chemotherapy. However, at his one-year... -
Survivor Spotlight: Randi Young and Sharon Schneider Found Their Footing with Team LUNGevity
Team LUNGevity attracts experienced athletes, newcomers, and everyone in between. Many run, bike, or swim in honor or in memory of someone diagnosed with lung cancer, but lung...
Patient Gateway